Contact Information: Contact: Zackary Irani 949-645-2111
Biomerica Board of Directors Adds New Member
| Source: Biomerica
NEWPORT BEACH, CA--(Marketwire - July 17, 2007) - Biomerica, Inc. (OTCBB : BMRA ), a global
provider of advanced diagnostic products for the early detection of medical
conditions, today announced that its board of directors has increased the
size of the board from five to six members and elected John Roehm,
President & CEO of Mollen Immunization Clinics of North America, to the
board. From 1989 to 2006, Mr. Roehm served in a broad range of leadership
positions with Albertsons / American Stores (Sav-on & Osco) including its
Director of Pharmacy Marketing since 1999. He holds a B.S. degree in
Pharmacy from Massachusetts College of Pharmacy.
"John's broad experience in chain drug pharmacy marketing and management
will bring an enormous wealth of OTC and consumer knowledge to our
Company," said Biomerica CEO and Chairman Zack Irani. "We are pleased that
John has joined our Board as we increase our focus on the OTC drug store
market."
"Biomerica is well positioned to take advantage of the growth in the
consumer healthcare market," Mr. Roehm said. "I look forward to
contributing to the Company as it grows."
The Company also recently elected Jane F. Emerson, M.D., Ph.D., Chief of
Clinical Pathology and Vice-Chair for Clinical Affairs, Department of
Pathology and Laboratory Medicine University of California, Irvine, to the
board.
About Biomerica (OTCBB : BMRA )
Biomerica, Inc. (www.biomerica.com) is a global medical technology company,
based in Newport Beach, CA. The Company manufactures and markets advanced
diagnostic products used at home, in hospitals, and in physicians' offices
for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements. Certain information included in
this press release (as well as information included in oral statements or
other written statements made or to be made by Biomerica) contains
statements that are forward-looking; such as statements relating to
intended launch dates, sales potential, significant benefits, market size,
growth of business, favorable positions, expansion, expected orders,
leading market positions, anticipated future revenues or production volume
of the Company, success of product and new product offerings. Such
forward-looking information involves important risks and uncertainties that
could significantly affect anticipated results in the future, and
accordingly, such results may differ materially from those expressed in any
forward-looking statements made by or on behalf of Biomerica. The potential
risks and uncertainties include, among others, fluctuations in the
Company's operating results due to its business model and expansion plans,
downturns in international and or national economies, the Company's ability
to raise additional capital, the competitive environment in which the
Company will be competing, and the Company's dependence on strategic
relationships. The Company is under no obligation to update any
forward-looking statements after the date of this release.